Probitas Pharma Completes Acquisition of SeraCare, Inc.

September 25, 2001 — LOS ANGELES, CA — SeraCare, Inc. recently announced that Instituto Grifols, S.A., a subsidiary of Probitas Pharma, S.A., has completed its acquisition of SeraCare, Inc. for $116.5 million in cash plus the assumption of approximately $30.0 million in debt.

SeraCare also announced that at the close of business on September 24, 2001, it had effected the spin-off of its distribution and manufacturing division, SeraCare Life Sciences, Inc.

Pursuant to the terms of the Probitas Pharma acquisition, SeraCare stockholders of record as of the close of business on September 24 will receive a cash payment of $6.8513 for every share of SeraCare held.

“The completion of this acquisition represents an important strategic step in our company’s growth plans. We look forward to harnessing the value of the plasma collection assets, operations and the unique talents that Barry and the rest of SeraCare’s senior management bring to our company,” said Victor Grifols, CEO of Instituto Grifols.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.